Skip to main content
. 2022 May 5;5(2):368–379. doi: 10.20517/cdr.2021.148

Figure 3.

Figure 3

Therapy schematic. Broad-reaching drugs may lend to more durable responses as resistance can arise more rapidly to targeted therapy. Modulating more broad cancer hallmarks - like immune and metabolic targets - may offer smarter drug targets.